Cost effectiveness of a GP delivered medication review to reduce polypharmacy and potentially inappropriate prescribing in older patients with multimorbidity in Irish primary care: the SPPiRE cluster randomised controlled trial
The European Journal of Health Economics · 2025
DOI: 10.1007/s10198-024-01718-7 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The European Journal of Health Economics, 2025. Verfasst von Paddy Gillespie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics and Policy Analysis Centre, Institute for Lifecourse and Society, CURAM, SFI Research Centre for Medical Devices, School of Business…. Hauptthemen laut MEDLINE: Primary Health Care, Polypharmacy, Inappropriate Prescribing, General Practitioners. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Board, National University Ireland, Galway.
Themen: Medikationssicherheit
Abstract (Originalsprache)
Background
Evidence on the cost effectiveness of deprescribing in multimorbidity is limited.
Objective
To investigate the cost effectiveness of a general practitioner (GP) delivered, individualised medication review to reduce polypharmacy and potentially inappropriate prescribing in older patients with multimorbidity in Irish primary care.
Methods
Within trial economic evaluation, from a healthcare perspective and based on a cluster randomised controlled trial with a 6 month follow up and 403 patients (208 Intervention and 195 Control) recruited between April 2017 and December 2019.
Intervention
GPs used the SPPiRE website which contained educational materials and a template to support a web-based individualised medication review. Control GPs delivered usual care. Incremental costs, quality adjusted life years (QALYs) generated using the EQ-5D-5L instrument, and expected cost effectiveness were estimated using multilevel modelling and multiple imputation techniques. Uncertainty was explored using parametric, deterministic and probabilistic methods.
Results
On average, the SPPiRE intervention was dominant over usual care, with non-statistically significant mean cost savings of €410 (95% confidence interval (CI): − 2211, 1409) and mean health gains of 0.014 QALYs (95% CI − 0.011, 0.039). At cost effectiveness threshold values of €20,000 and €45,000 per QALY, the probability of SPPiRE being cost effective was 0.993 and 0.988. Results were sensitive to missing data and data collection period.
Conclusions
The study observed a pattern towards dominance for the SPPiRE intervention, with high expected cost effectiveness. Notably, observed differences in costs and outcomes were consistent with chance, and missing data and related uncertainty was non trivial. The cost effectiveness evidence may be considered promising but equivocal.
Trial registration
ISRCTN: 12752680, 20th October 2016.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Health Economics and Policy Analysis Centre, Institute for Lifecourse and Society, CURAM, SFI Research Centre for Medical Devices, School of Business and Economics, University of Galway, University Road, Galway, Ireland…
- School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin, Ireland.
- Discipline of Public Health and Primary Care, Institute of Population Health, Trinity College Dublin, Dublin, Ireland.
- Health Economics and Policy Analysis Centre, Institute for Lifecourse and Society, CURAM, SFI Research Centre for Medical Devices, School of Business and Economics, University of Galway, University Road, Galway, Ireland.
- School of Population Health, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin, Ireland.
- Department of General Practice, University College Cork, Cork, Ireland.
Förderung
- Health Research Board
- National University Ireland, Galway
Zitieren
APA
Gillespie, P., Moriarty, F., Smith, S. M., Hobbins, A., Walsh, S., Clyne, B., Boland, F., McEnteggart, T., Flood, M., Wallace, E., McCarthy, C., & SPPiRE Study team (2025). Cost effectiveness of a GP delivered medication review to reduce polypharmacy and potentially inappropriate prescribing in older patients with multimorbidity in Irish primary care: the SPPiRE cluster randomised controlled trial. The European Journal of Health Economics. https://doi.org/10.1007/s10198-024-01718-7
Vancouver
Gillespie P, Moriarty F, Smith SM, Hobbins A, Walsh S, Clyne B, et al. Cost effectiveness of a GP delivered medication review to reduce polypharmacy and potentially inappropriate prescribing in older patients with multimorbidity in Irish primary care: the SPPiRE cluster randomised controlled trial. The European Journal of Health Economics. 2025. doi:10.1007/s10198-024-01718-7
BibTeX
@article{Gillespie2025,
author = {Gillespie, Paddy and Moriarty, Frank and Smith, Susan M and Hobbins, Anna and Walsh, Sharon and Clyne, Barbara and Boland, Fiona and McEnteggart, Tara and Flood, Michelle and Wallace, Emma and McCarthy, Caroline and SPPiRE Study team, SPPiRE Study team},
title = {Cost effectiveness of a GP delivered medication review to reduce polypharmacy and potentially inappropriate prescribing in older patients with multimorbidity in Irish primary care: the SPPiRE cluster randomised controlled trial},
journal = {The European Journal of Health Economics},
year = {2025},
doi = {10.1007/s10198-024-01718-7}
}
EUVIMED